DK0573604T3 - Fremgangsmåde til behandling af osteoporosis - Google Patents

Fremgangsmåde til behandling af osteoporosis

Info

Publication number
DK0573604T3
DK0573604T3 DK92908494.5T DK92908494T DK0573604T3 DK 0573604 T3 DK0573604 T3 DK 0573604T3 DK 92908494 T DK92908494 T DK 92908494T DK 0573604 T3 DK0573604 T3 DK 0573604T3
Authority
DK
Denmark
Prior art keywords
treatment
subject
treating osteoporosis
phosphonate
bone
Prior art date
Application number
DK92908494.5T
Other languages
Danish (da)
English (en)
Inventor
Jocelyn Elaine Mcosker
Original Assignee
Procter & Gamble Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble Pharma filed Critical Procter & Gamble Pharma
Application granted granted Critical
Publication of DK0573604T3 publication Critical patent/DK0573604T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Removal Of Specific Substances (AREA)
DK92908494.5T 1991-02-26 1992-01-31 Fremgangsmåde til behandling af osteoporosis DK0573604T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66177791A 1991-02-26 1991-02-26

Publications (1)

Publication Number Publication Date
DK0573604T3 true DK0573604T3 (da) 1995-05-29

Family

ID=24655074

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92908494.5T DK0573604T3 (da) 1991-02-26 1992-01-31 Fremgangsmåde til behandling af osteoporosis

Country Status (18)

Country Link
US (1) US6329354B1 (fr)
EP (1) EP0573604B1 (fr)
JP (1) JP3727332B2 (fr)
KR (1) KR100240358B1 (fr)
AT (1) ATE119777T1 (fr)
AU (1) AU664368B2 (fr)
CA (1) CA2101275C (fr)
CZ (1) CZ282609B6 (fr)
DE (1) DE69201725T2 (fr)
DK (1) DK0573604T3 (fr)
ES (1) ES2069424T3 (fr)
HU (1) HU215124B (fr)
IE (1) IE65963B1 (fr)
NO (1) NO305581B1 (fr)
NZ (1) NZ241717A (fr)
RU (1) RU2113848C1 (fr)
SK (1) SK90093A3 (fr)
WO (1) WO1992014474A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07504672A (ja) * 1992-03-21 1995-05-25 エンテック　ゲゼルシャフト　フュア　エンドクリノロギッシェ　テヒノロギー　エム．ベー．ハー． 更年期骨粗鬆症の処置に対するエストリオールの使用
WO1994009017A1 (fr) * 1992-10-09 1994-04-28 The Upjohn Company Esters de biphosphonate de pyrimidine et acides (alcoxymethylphosphonyl)alkyle phosphoniques utilises comme anti-inflammatoires
US6399592B1 (en) 1992-12-23 2002-06-04 Merck & Co., Inc. Bishphosphonate/estrogen synergistic therapy for treating and preventing bone loss
AU5953894A (en) * 1992-12-23 1994-07-19 Merck & Co., Inc. Bisphosphonate/estrogen therapy for treating and preventing bone loss
CA2162470C (fr) * 1993-05-15 1998-06-16 Walter Preis Comprime a biodisponibilite amelioree, renfermant de l'acide dichloromethylenediphosphonique comme principe actif
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
KR100385697B1 (ko) * 1994-12-28 2003-08-21 가도르 에스. 에이. 올파드로네이트를포함하는골체량동화성조성물
DE19635883A1 (de) * 1996-09-04 1998-03-05 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit einer Östriol enthaltenden Wirkstoffkombination
US6376477B2 (en) 1996-11-25 2002-04-23 Merck & Co., Inc. Combination of an agent that binds to the androgen receptor and a bisphosphonic acid in the prevention and/or treatment of diseases involving calcium or phosphate metabolism
WO1998023274A1 (fr) * 1996-11-25 1998-06-04 Merck & Co., Inc. Agents androgene et bisphosphonique coadministres pour traiter des maladies
US6692763B1 (en) * 1998-11-19 2004-02-17 The Regents Of The University Of California Methods for treating postmenopausal women using ultra-low doses of estrogen
AR013994A1 (es) * 1998-10-30 2001-01-31 Gador Sa Procedimiento y preparaciones que modulan selectivamente la funcion del osteoblasto para la prevencion y tratamiento de las osteopatias fragilizantes.
US6579860B1 (en) * 1998-12-25 2003-06-17 Toray Industries, Inc. Interleukin-6 production inhibitors
US6339078B1 (en) 1999-07-20 2002-01-15 University Of Florida Research Foundation, Inc. Methods of prevention and treatment of ischemic damage
US6326365B1 (en) 1999-07-20 2001-12-04 Apollo Biopharmaceutics, Inc. Methods of prevention and treatment of ischemic damage
US7335650B2 (en) 2000-01-14 2008-02-26 Sterix Limited Composition
US6653298B2 (en) 2000-01-14 2003-11-25 Sterix Limited Composition
US20040038946A1 (en) * 2001-04-27 2004-02-26 Wilson Lon J. Fullerene-based drugs targeted to bone
NZ584219A (en) * 2007-11-30 2012-03-30 Novartis Ag C2-c5-alkyl-imidazole-bisphosphonates
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
SI2459176T1 (en) 2009-07-31 2018-01-31 Gruenenthal Gmbh Crystallization process and bioavailability
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
WO2017208070A1 (fr) 2016-05-31 2017-12-07 Grünenthal GmbH Acide bisphosphonique et coformeurs avec lysine, glycine, nicotinamide pour le traitement de la polyarthrite psoriasique

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3553314A (en) 1968-12-23 1971-01-05 Procter & Gamble Oral compositions for calculus retardation
US3683080A (en) 1970-08-28 1972-08-08 Procter & Gamble Compositions for inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue
EP0088462A3 (fr) * 1982-03-01 1984-06-06 The Procter & Gamble Company Composition anti-inflammatoire et anti-rhumatisante contenant un organophosphonate et un stéroide
EP0381296B1 (fr) * 1984-04-30 1994-11-30 THE PROCTER & GAMBLE COMPANY Equipement pour utilisation dans le traitement de l'ostéoporose
US4761406A (en) 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
IL86951A (en) 1987-07-06 1996-07-23 Procter & Gamble Pharma Methylene phosphonoalkylphosphinates and pharmaceutical preparations containing them

Also Published As

Publication number Publication date
SK90093A3 (en) 1994-09-07
DE69201725D1 (de) 1995-04-20
AU664368B2 (en) 1995-11-16
CA2101275C (fr) 1998-08-04
CZ175593A3 (en) 1994-04-13
NO933044D0 (no) 1993-08-26
HUT66429A (en) 1994-11-28
KR100240358B1 (ko) 2000-02-01
EP0573604B1 (fr) 1995-03-15
DE69201725T2 (de) 1996-04-18
AU1643392A (en) 1992-09-15
RU2113848C1 (ru) 1998-06-27
CZ282609B6 (cs) 1997-08-13
HU215124B (hu) 1998-09-28
JPH06505501A (ja) 1994-06-23
EP0573604A1 (fr) 1993-12-15
HU9302407D0 (en) 1993-11-29
NO305581B1 (no) 1999-06-28
NO933044L (no) 1993-08-26
IE920584A1 (en) 1992-08-26
ES2069424T3 (es) 1995-05-01
NZ241717A (en) 1997-02-24
WO1992014474A1 (fr) 1992-09-03
ATE119777T1 (de) 1995-04-15
IE65963B1 (en) 1995-11-29
CA2101275A1 (fr) 1992-08-27
US6329354B1 (en) 2001-12-11
JP3727332B2 (ja) 2005-12-14

Similar Documents

Publication Publication Date Title
DK0573604T3 (da) Fremgangsmåde til behandling af osteoporosis
RU93054017A (ru) Способ лечения остеопороза, композиция для лечения остеопороза, применение активно действующего на кости фосфоната и эстрогенного гормона для лечения остеопороза
ATE105482T1 (de) Behandlung von krebs mit somatostatin und mit analogen davon.
DE69631134D1 (de) Verfahren zur bekämpfung infektiöser krankheiten unter verwendung dikationischer bis-benzimidazole
DE69616376D1 (de) Verwendung von Tiagabin zur Behandlung von Schlafstörungen
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
ATE150646T1 (de) Behandlung von peridontalkrankheiten mit alendronat
DE69533991D1 (de) Dipeptide, die die ausschüttung von wachstumshormonen stimulieren
DE69634900D1 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
DK0918516T3 (da) Fremgangsmåde til forebyggelse af skeletale problemer hos fjerkræ
ATE218350T1 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
ATE161423T1 (de) Verwendung von phosphinate zur behandlung der osteoporose
EA199700183A1 (ru) Способ уменьшения риска невертебральных переломов костей
EP0515434A4 (en) Method for treating intestinal diseases
DE60015791D1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
ATE291918T1 (de) Kombinationstherapie zur behandlung von tumoren
ATE297739T1 (de) Endothelin-antagonisten zur behandlung von herzversagen
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
ATE249837T1 (de) Caspase 8-inhibitoren zur immunsuppression
DE69220229T2 (de) Somatotropin zur erhoehung der reproduktiven leistung in rinder
CO4410200A1 (es) Metodos para el tratamiento de osteoporosis usando fosfona- tos activos de huesos y hormonas paratiroidales
AR001226A1 (es) Métodos para el tratamiento de la osteoporosis utilizando fosofonatos activos y hormona paratiroidea
UA43389C2 (uk) Спосіб зниження рівнів кальцію у сироватці